Sandy D. Der

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.

Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 31, 2017

A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.

A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer

Published: February 14, 2016

Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung Signature.

Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung Signature.

Journal: PLoS currents

Published: November 12, 2015

Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.

Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 23, 2015

Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.

Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.

Journal: PloS one

Published: July 13, 2014

Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.

Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 06, 2013

Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.

Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.

Journal: Cancer medicine

Published: October 08, 2013

Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis.

Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis.

Journal: PloS one

Published: July 07, 2013

NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells.

NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells.

Journal: European journal of immunology

Published: November 14, 2012

Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies.

Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies.

Journal: Genome medicine

Published: August 02, 2012

Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue.

Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: April 28, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026